-
Ferrostatin-1 (Fer-1): Mechanism and Evidence
2026-10-09
Ferrostatin-1, also called Fer-1, is a research probe that suppresses lipid peroxidation associated with ferroptosis. Its reported cellular potency is context-dependent, and Fer-1 rescue alone cannot distinguish ferroptosis from other ROS-associated death pathways.
-
VX-765 and Caspase-1 Research Context
2026-10-09
A source-grounded overview of VX-765, VRT-043198, caspase-1 signaling, and pyroptosis research. It compares supplier-reported pharmacology with a 2026 pre-proof study of cordycepin plus photodynamic therapy in breast cancer cells, while emphasizing evidence strength, mechanistic uncertainty, and applicability limits.
-
Dextromethorphan Hydrobromide: Evidence in Context
2026-10-08
A source-grounded overview of Dextromethorphan hydrobromide, its proposed NMDA receptor antagonist activity, and the limits of current evidence for neuroprotection, excitotoxicity, and cerebral ischemia research.
-
Porous Graphene MSI Maps Ethanol-Linked Brain Asymmetry
2026-10-08
A 2026 Chemical Engineering Journal study introduces laser-induced graphene as a matrix-free substrate for high-resolution laser desorption/ionization mass spectrometry imaging. Applied to mice after single-dose ethanol intoxication, the platform revealed time-dependent left–right differences in nine brain lipid species, highlighting both an analytical advance and a biological question about metabolic laterality.
-
Flavopiridol and ER Stress: Evidence Review
2026-10-07
A source-grounded overview of Flavopiridol (L868275), its CDK-inhibition context, and what current evidence does—and does not—show about endoplasmic reticulum stress, intestinal stem cells, cell-cycle arrest, and cancer research.
-
NMDAR–Cav2.1 Recruitment in PV Interneurons
2026-10-07
Singh et al. show that developmental NMDAR signaling in prospective parvalbumin interneurons is required for mature Cav2.1-supported GABA release, linking receptor development to inhibitory synaptic function. The study positions omega-agatoxin IVA as a mechanistic probe of this pathway while emphasizing that its findings are developmental neurophysiology evidence rather than proof of therapeutic efficacy.
-
CHIR-99021 and the Translational Logic of WNT
2026-10-06
A source-grounded perspective on CHIR-99021 (CT99021) that connects GSK-3 biology with stem-cell state control, human intestinal organoid evidence, and translational decision-making without treating pathway modulation as a universal differentiation recipe.
-
DiscoveryProbe Stem Cell Library: Evidence Overview
2026-10-06
The DiscoveryProbe Stem Cell Compound Library Plus is a 280-compound collection positioned for stem cell pathway profiling and phenotypic screening. The strongest supplied evidence comes from an accepted manuscript describing a high-content screen in Schistosoma mansoni, where selected compounds reduced neoblast proliferation and constrained parasite development; the findings support a research platform, not broad claims about human stem cells or validated therapeutic mechanisms.
-
Five Questions About Cy5 Luciferase mRNA Evidence
2026-10-05
A source-grounded guide to interpreting EZ Cap Cy5 Firefly Luciferase mRNA, separating reporter principles and supplier claims from independent evidence, and defining what dual fluorescence–bioluminescence studies can and cannot show.
-
BMN 673: Evidence, Mechanism, and Limits
2026-10-04
BMN 673, also known as talazoparib, is a PARP inhibitor studied in the context of DNA repair deficiency. This overview explains what recent BRCA2 research shows, how strong the evidence is, and why mechanistic findings should not be treated as proof of clinical benefit across all tumors.
-
Gap19 and Cx43: Reading Hemichannel Evidence
2026-10-03
Gap19 is a selective connexin 43 hemichannel blocker for investigating astrocyte signaling, neuroprotection in cerebral ischemia, and inflammatory mechanisms. This evidence-led analysis distinguishes channel selectivity from broader Cx43 pathway effects and connects the product literature with macrophage NF-κB findings.
-
CLK2 and Platinum Resistance in Ovarian Cancer
2026-10-02
The reference study identifies CLK2 as a determinant of platinum resistance in ovarian cancer and defines a CLK2–BRCA1 DNA-repair mechanism. Its tissue, cellular, and xenograft evidence supports CLK2 as a preclinical target while also clarifying why pharmacological selectivity must be tested carefully.
-
Doxorubicin: From DNA Damage to Translational Risk
2026-10-01
Doxorubicin and Adriamycin remain powerful reference compounds for connecting DNA damage, apoptosis induction in cancer cells, and cardiotoxicity risk. This thought-leadership guide shows how translational teams can combine mechanistic assays, iPSC-derived cardiomyocytes, and deep-learning-enabled phenotyping to turn a familiar cancer chemotherapy drug into a strategic decision tool.
-
GANT61 Workflow for GLI Inhibition Research
2026-10-01
GANT61 enables direct interrogation of GLI1/GLI2 activity without relying solely on upstream Hedgehog receptor blockade. This workflow connects transcriptional assays with tumor-cell phenotyping and immune-microenvironment studies, helping researchers test how GLI signaling contributes to proliferation, immune evasion, and treatment resistance.
-
Nuclear mTORC1 Revealed by TerminaTOR
2026-09-30
The reference study introduces TerminaTOR, a genetically encodable inhibitor that can selectively suppress mTORC1 at defined subcellular locations. By separating lysosomal from nuclear mTORC1 activity, the work shows that nuclear mTORC1 regulates transcription of CCAAT motif-containing genes rather than simply duplicating canonical lysosomal outputs.